Akari Therapeutics, Plc (AKTX)
| Previous close | 1.1700 |
| Open | 1.1400 |
| Bid | 1.0600 x 100 |
| Ask | 0.0000 x 0 |
| Day's range | 1.2010 - 1.2010 |
| 52-week range | 1.0780 - 5.5000 |
| Volume | |
| Avg. volume | 12,550 |
| Market cap | 9.516M |
| Beta (5Y monthly) | 0.96 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.0400 |
| Earnings date | 29 Apr 2024 - 03 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 80.00 |
GlobeNewswireAkari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024
BOSTON and LONDON, April 15, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the company will present new pre-clinical data on investigational long-acting PAS-nomacopan including drug effect on electroretinography (ERG) testing in a blue light model at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting in Seattle. Akari Chief S
Simply Wall St.Akari Therapeutics Insider Ups Holding By 69% During Year
Viewing insider transactions for Akari Therapeutics, Plc's ( NASDAQ:AKTX ) over the last year, we see that insiders...
- GlobeNewswire
Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights
BOSTON and LONDON, April 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, has reported financial results for the full year 2023 as well as recent company highlights. “Amidst challenging economic conditions during 2023 in the biotech sector and beyond, the Akari team advanced our Phase 3 and pre-clinical development programs and paved the way for a merger that, upon closi
